search
Back to results

Strategies to Improve the HIV Care Continuum Among Key Populations in India

Primary Purpose

HIV Infections

Status
Active
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Incentives
Integrated Care Centers
Sponsored by
Johns Hopkins University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for HIV Infections focused on measuring people who inject drugs, men who have sex with men, HIV, India

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Speaks Hindi, English, or local language
  • HIV-positive
  • Antiretroviral therapy (ART) naive or has used ART less than 12 months
  • Registered client at the local integrated care center (ICC), which serves either people who inject drugs (PWID) or men who have sex with men (MSM).

Exclusion Criteria:

  • Not competent to provide informed consent or participate in the study.
  • Receives HIV care in the private sector
  • Plans to migrate in next 12 months

Sites / Locations

  • YR Gaitonde Center for AIDS Research and Education

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

Integrated care centers

ICC + incentives

Arm Description

Participants in the active comparator arm have access to integrated care centers (ICCs)

Participants in the experimental arm have access to the ICC intervention and the incentive intervention

Outcomes

Primary Outcome Measures

Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA <150 copies/mL

Secondary Outcome Measures

Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA <150 copies/mL
Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA <150 copies/mL
Proportion of Participants Surviving With Viral Suppression
Viral suppression defined as HIV RNA <150 copies/mL
Proportion of Participants With Viral Suppression at One or More Follow-up Visits
Proportion with viral suppression (HIV RNA <150 copies/mL) at one or more follow-up visits
Antiretroviral Therapy (ART) Initiation
Rate of ART initiation among those naive to ART at baseline. This is reported as the proportion of participants who initiated ART.
Retention to HIV Care
Proportion of participants who attended one or more visits to a government ART clinic in both the 0 to 6 month period and the 6 to 12 month period.
ART Adherence
Proportion of participants who had a medication possession ratio of 0.9 or higher after starting ART
Mortality
All-cause mortality

Full Information

First Posted
November 18, 2016
Last Updated
August 7, 2023
Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA), YR Gaitonde Centre for AIDS Research and Education, Elton John AIDS Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT02969915
Brief Title
Strategies to Improve the HIV Care Continuum Among Key Populations in India
Official Title
Strategies to Improve the HIV Care Continuum Among Key Populations in India
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
October 30, 2017 (Actual)
Primary Completion Date
March 23, 2020 (Actual)
Study Completion Date
April 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Johns Hopkins University
Collaborators
National Institute on Drug Abuse (NIDA), YR Gaitonde Centre for AIDS Research and Education, Elton John AIDS Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This clinical trial will compare the effectiveness of integrated care centers vs. integrated care centers plus HIV patient treatment incentives for achieving HIV treatment targets among people who inject drugs and men who have sex with men in India. The investigators will also assess cost-effectiveness and barriers and facilitators to implementation through targeted mixed-methods approaches. This study is a model for improving HIV treatment outcomes in key populations in low to middle-income countries.
Detailed Description
The trajectory of the HIV epidemic in coming decades will be determined by the degree to which we can identify infected persons and engage them in care - a point implicit in the ambitious UNAIDS "90-90-90" target, which sets 90% goals for HIV diagnosis, linkage of infected persons to sustained antiretroviral therapy (ART), and viral suppression in those treated. Meeting this target requires successful engagement of difficult to reach populations, such as people who inject drugs (PWID) and men who have sex with men (MSM), who bear a disproportionate share of the epidemic, particularly in low to middle income countries. Our team is nearing completion of a multi-site cluster-randomized trial in India to assess the effectiveness of integrated care centers (ICCs) for PWID and MSM compared to usual care. ICC process measures from the first year show robust uptake of HIV counseling and testing, the primary outcome for that trial, but slower than anticipated ART uptake. Demand-side interventions in public health (such as treatment incentives) can be particularly effective when paired with optimized treatment accessibility (i.e., supply). Consequently, the investigators propose to examine whether provision of HIV care and treatment incentives to ICC clients will improve overall utilization of the clinics and downstream HIV care continuum outcomes. The investigators propose a hybrid effectiveness-implementation design. This will include a 16-site, pair-matched cluster randomized trial to compare the effectiveness of adding of HIV care incentives to ICCs (ICC+) versus standard ICCs on HIV care continuum outcomes, including ART initiation, adherence and viral suppression. Effectiveness will be compared at the ICC level (from a cohort of HIV-infected ART-eligible clients followed in each ICC and process measures deriving from all ICC clients) and at the community-level through a cross-sectional sample accrued via respondent-driven sampling (RDS) 2 years after initiation of the intervention. Because PWID and MSM will be sampled independently from the ICCs in the RDS, it provides an opportunity to characterize outcomes like community viral load and HIV incidence, reflecting impact within the broader PWID/MSM communities. As an exploratory sub-aim, we will use a rigorous scientific design to assess the effects of withdrawing (vs. continuing) incentives beyond the initial intervention phase. Additionally, the investigators will determine the cost-effectiveness of the ICC+ intervention.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
people who inject drugs, men who have sex with men, HIV, India

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Matched-pair cluster-randomized trial
Masking
None (Open Label)
Allocation
Randomized
Enrollment
2314 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Integrated care centers
Arm Type
Active Comparator
Arm Description
Participants in the active comparator arm have access to integrated care centers (ICCs)
Arm Title
ICC + incentives
Arm Type
Experimental
Arm Description
Participants in the experimental arm have access to the ICC intervention and the incentive intervention
Intervention Type
Behavioral
Intervention Name(s)
Incentives
Other Intervention Name(s)
ICC+
Intervention Description
Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
Intervention Type
Behavioral
Intervention Name(s)
Integrated Care Centers
Other Intervention Name(s)
ICC
Intervention Description
ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
Primary Outcome Measure Information:
Title
Proportion of Participants Surviving With Viral Suppression
Description
Viral suppression defined as HIV RNA <150 copies/mL
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Proportion of Participants Surviving With Viral Suppression
Description
Viral suppression defined as HIV RNA <150 copies/mL
Time Frame
6 months
Title
Proportion of Participants Surviving With Viral Suppression
Description
Viral suppression defined as HIV RNA <150 copies/mL
Time Frame
18 months
Title
Proportion of Participants Surviving With Viral Suppression
Description
Viral suppression defined as HIV RNA <150 copies/mL
Time Frame
24 months
Title
Proportion of Participants With Viral Suppression at One or More Follow-up Visits
Description
Proportion with viral suppression (HIV RNA <150 copies/mL) at one or more follow-up visits
Time Frame
24 months
Title
Antiretroviral Therapy (ART) Initiation
Description
Rate of ART initiation among those naive to ART at baseline. This is reported as the proportion of participants who initiated ART.
Time Frame
12 months
Title
Retention to HIV Care
Description
Proportion of participants who attended one or more visits to a government ART clinic in both the 0 to 6 month period and the 6 to 12 month period.
Time Frame
12 months
Title
ART Adherence
Description
Proportion of participants who had a medication possession ratio of 0.9 or higher after starting ART
Time Frame
12 months
Title
Mortality
Description
All-cause mortality
Time Frame
12 months
Other Pre-specified Outcome Measures:
Title
HIV Testing Rate in Integrated Care Centers (ICCs)
Description
HIV tests done per unit time
Time Frame
6, 12, 18, and 24 months
Title
Rate of New HIV Diagnoses at ICCs
Description
New HIV diagnoses per unit time
Time Frame
6, 12, 18, and 24 months
Title
Qualitative Evaluation of Incentive Intervention
Description
In-depth interviews with study participants and ICC staff
Time Frame
24-36 months
Title
Recent HIV Testing, Community-level (Respondent-driven Sampling [RDS] Survey)
Description
Proportion reporting HIV test in prior 12 months among RDS survey participants
Time Frame
36-48 months
Title
Awareness of HIV-positive Status, Community-level (RDS Survey)
Description
Proportion of HIV-positive participants aware of their status
Time Frame
36-48 months
Title
Recent HIV Care Visit, Community-level (RDS Survey)
Description
Proportion of HIV-positive participants with treatment visit in prior 6 months
Time Frame
36-48 months
Title
Current ART Use, Community-level (RDS Survey)
Description
Proportion of HIV-positive participants with ART use in prior 30 days
Time Frame
36-48 months
Title
Viral Load Suppression, Community-level (RDS Survey)
Description
Proportion of HIV-positive participants with suppressed viral load (HIV RNA <150 c/mL)
Time Frame
36-48 months
Title
Prevalence of Viremic Persons, Community-level (RDS Survey)
Description
Proportion of all participants (HIV-negative and HIV-positive) with a measured HIV RNA ≥150 copies/mL.
Time Frame
36-48 months
Title
HIV Incidence, Community-level (RDS Survey)
Description
Estimated with a validated multi-assay algorithm measured in HIV-positive participants
Time Frame
36-48 months
Title
Costs Per Quality-adjusted Life Year Gained
Description
Evaluation of intervention costs and cost-effectiveness
Time Frame
6, 12, 18, and 24 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Speaks Hindi, English, or local language HIV-positive Antiretroviral therapy (ART) naive or has used ART less than 12 months Registered client at the local integrated care center (ICC), which serves either people who inject drugs (PWID) or men who have sex with men (MSM). Exclusion Criteria: Not competent to provide informed consent or participate in the study. Receives HIV care in the private sector Plans to migrate in next 12 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shruti H Mehta, PhD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Gregory M Lucas, MD
Organizational Affiliation
Johns Hopkins University
Official's Role
Principal Investigator
Facility Information:
Facility Name
YR Gaitonde Center for AIDS Research and Education
City
Chennai
State/Province
Tamil Nadu
ZIP/Postal Code
600010
Country
India

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
The investigators will require prospective collaborators to submit concept sheets to the study PIs that include a brief summary of the proposed hypothesis, summary of research methods, specific data or specimens that are being requested, and plans for analysis. Reasonable requests that address relevant scientific questions will be welcomed and supported to the extent possible.

Learn more about this trial

Strategies to Improve the HIV Care Continuum Among Key Populations in India

We'll reach out to this number within 24 hrs